ELISA/assay

Rat Receptor Activator of Nuclear Factor Kb Ligand ELISA Kit

MBS725602

48-Strip-Wells-(Comp

470 USD

ELISA Kit

Rat Receptor Activator of Nuclear Factor Kb Ligand ELISA Kit

Receptor Activator of Nuclear Factor Kb Ligand

RANKL; Tumor necrosis factor ligand superfamily member 11; tumor necrosis factor ligand superfamily member 11; osteoprotegerin ligand; osteoclast differentiation factor; TNF-related activation-induced cytokine; receptor activator of nuclear factor kappa B ligand; receptor activator of nuclear factor kappa-B ligand; tumor necrosis factor (ligand) superfamily, member 11; Osteoclast differentiation factor; ODF; Osteoprotegerin ligand; OPGL; Receptor activator of nuclear factor kappa-B ligand; RANKL; TNF-related activation-induced cytokine; TRANCE; CD_antigen: CD254Cleaved into the following 2 chains:Tumor necrosis factor ligand superfamily member 11, membrane form; Tumor necrosis factor ligand superfamily member 11, soluble form

RANKL

TNFSF11; TNFSF11; ODF; OPGL; sOdf; CD254; OPTB2; RANKL; TRANCE; hRANKL2; OPGL; RANKL; TRANCE; ODF; OPGL; RANKL; TRANCE

TNF11_HUMAN

Rat

This assay has high sensitivity and excellent specificity for detection of RANKL. No significant cross-reactivity or interference between RANKL and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between RANKL and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, cell culture supernatants, body fluid and tissue homogenate. Assay Type: Competitive or Sandwich. Sensitivity: 0.1 ng/mL.

Immunology

Intended Uses This RANKL ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Rat RANKL. This ELISA kit for research use only, not for therapeutic or diagnostic applications!. Principle of the Assay: RANKL ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-RANKL antibody and an RANKL-HRP conjugate. The assay sample and buffer are incubated together with RANKL-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the RANKL concentration since RANKL from samples and RANKL-HRP conjugate compete for the anti-RANKL antibody binding site. Since the number of sites is limited, as more sites are occupied by RANKL from the sample, fewer sites are left to bind RANKL-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The RANKL concentration in each sample is interpolated from this standard curve.

2612922

AAB86811.1

30,523 Da

Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); IL6-mediated Signaling Events Pathway (137932); NF-kappa B Signaling Pathway (634527); Osteoblast Signaling Pathway (198842); Osteoclast Signaling Pathway (198769); Osteoclast Differentiation Pathway (193147); Osteoclast Differentiation Pathway (193096); Prolactin Signaling Pathway (814182); Prolactin Signaling Pathway (814248)

This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found. [provided by RefSeq, Jul 2008]

TNFSF11: Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. Homotrimer. Up-regulated by T-cell receptor stimulation. Highest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid. Belongs to the tumor necrosis factor family. 3 isoforms of the human protein are produced by alternative splicing. Protein type: Membrane protein, integral. Chromosomal Location of Human Ortholog: 13q14. Cellular Component: extracellular space; integral to plasma membrane; cytoplasm; extracellular region. Molecular Function: cytokine activity; tumor necrosis factor receptor superfamily binding; tumor necrosis factor receptor binding. Biological Process: ossification; positive regulation of I-kappaB kinase/NF-kappaB cascade; positive regulation of osteoclast differentiation; cytokine and chemokine mediated signaling pathway; mammary gland epithelial cell proliferation; osteoclast differentiation; activation of JNK activity; activation of NF-kappaB transcription factor; positive regulation of corticotropin-releasing hormone secretion; positive regulation of homotypic cell-cell adhesion; calcium ion homeostasis; positive regulation of MAP kinase activity; monocyte chemotaxis; positive regulation of protein kinase B signaling cascade; organ morphogenesis; tumor necrosis factor-mediated signaling pathway; positive regulation of bone resorption; positive regulation of transcription factor activity; immune response; positive regulation of transcription from RNA polymerase II promoter; positive regulation of T cell activation; protein homooligomerization; bone resorption. Disease: Osteopetrosis, Autosomal Recessive 2

48-Strip-Wells-(Competitive)

470 USD

48-Strip-Wells-(Sandwich)

470

96-Strip-Wells-(Competitive)

675

96-Strip-Wells-(Sandwich)

675